Influence of variants of Fcg receptor IIA on the European league against rheumatism responses to anti-tumour necrosis fa
- PDF / 164,328 Bytes
- 2 Pages / 595.276 x 793.701 pts Page_size
- 95 Downloads / 130 Views
POSTER PRESENTATION
Open Access
Influence of variants of Fcg receptor IIA on the European league against rheumatism responses to anti-tumour necrosis factor alpha therapy in psoriatic arthritis J Ramirez1*, J L Fernadez-Sueiro4, R Lopez2, C Montilla, B Suarez2, C Moll1, R Rodriguez2, F Blanco4, M Alsina3, R Sanmarti1, F Lozano2, J Cañete1 From 5th European Workshop on Immune-Mediated Inflammatory Diseases Sitges-Barcelona, Spain. 1-3 December 2010 Introduction The efficacy of biological therapies currently used in psoriatic arthritis depends not only on their blocking effect on the targeted molecule but also on the affinity of genetically defined variants of the Fc-gamma receptors for the constant portion (Fc fragment of IgG1). Aim To determine whether polymorphisms in Fc-gamma receptor IIA influence clinical efficacy in patients with psoriatic arthritis treated with tumor necrosis factor alpha inhibitors. Patients and methods The study population comprised 110 patients (52.7% males and 47.3% females) with psoriatic arthritis refractory to 15 mg or more of methotrexate/week. Infliximab (33.6%), etanercept (50.9%) or adalimumab (15.5%) were initiated, and patients were evaluated after 12 and 24 weeks using the EULAR response criteria. Genotyping of FCGR IIA-H131R polymorphism was performed by allele-specific PCR and PCR sequence-based typing. The chi-square test was used to compare response rates across Fc-gamma receptor IIA genotype.
affinity alleles (FCGRIIA RR) (Tables 1 and 2). However, there was a trend to a better response among patients with high affinity alleles.
Conclusion These results suggest that FCGR IIA-H131R polymorphism has low influence in the clinical efficacy of anti-TNF therapies in patients with psoriatic arthritis. Although different to previously reported results in rheumatoid arthritis [1], these results can be explained because of the better and more prolonged response to anti-TNF therapy in psoriatic arthritis than in rheumatoid arthritis. In addition, in this study we analyzed patients with three different anti-TNF-alpha therapies.
Table 1 12 weeks EULAR Response FCGRIIA HH+HR
RR
Total
Null (%)
10.1
26.3
13.3
Moderate (%)
27.8
10.5
24.5
Good (%)
62.0
63.2
62.2
p = 0.086.
Table 2 24 weeks EULAR response FCGRIIA
Results No significant differences were found at 12 and 24 weeks in EULAR responses between patients with high affinity alleles (FCGRIIA HH/HR) and patients with low
HH+HR
RR
Total
Null (%)
8.9
26.3
13.3
Moderate (%)
27.8
15.8
25.5
Good (%)
63.3
57.9
62.2
p = 0.090. 1
Rheumatology, Hospital Clinic, Barcelona, Spain Full list of author information is available at the end of the article
© 2010 Ramirez et al; licensee BioMed Central Ltd.
Ramirez et al. Journal of Translational Medicine 2010, 8(Suppl 1):P38 http://www.translational-medicine.com/content/8/S1/P38
Page 2 of 2
Author details 1 Rheumatology, Hospital Clinic, Barcelona, Spain. 2Immunology, Hospital Clinic, Barcelona, Spain. 3Hospital Clinic, Barcelona, Spain. 4Rheumatology, Complejo
Data Loading...
